FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Estrid Høgdall

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Denmark

Procedures

Physiology

Pregnancy

Co-author Network

Publications

TOP 3
Sofie Leisby Antonsen; Jon Asmussen; Anne Kiil Berthelsen; Ib Jarle Christensen; Carsten L Fagö-Olsen; Rune Fisker; Estrid V S Høgdall; Kirsten Jochumsen; Annika Loft; Anne Lerberg Nielsen; Ann Tabor; Erik Søgaard Andersen; Claus Høgdall
SUVmax of (18)FDG PET/CT as a predictor of high-risk endometrial cancer patients.
Sofie Leisby Antonsen; Jon Asmussen; Anne Kiil Berthelsen; Ib Jarle Christensen; Junia Costa; Carsten L Fagö-Olsen; Rune Fisker; Mette Rodi Hansen; Estrid V S Høgdall; Lisa Neerup Jensen; Kirsten Jochumsen; Annika Loft; Lotte Nedergaard; Anne Lerberg Nielsen; Ingelise Qvist; Lene Sperling; Ann Tabor; Erik Søgaard Andersen; Claus Høgdall
MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study.
Morten H Sparholt; Lotte Nedergaard; Ib J Christensen; Mel C J Heeran; Claus K Høgdall; Estrid V S Høgdall
Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Estrid Høgdall (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sofie Leisby Antonsen; Jon Asmussen; Anne Kiil Berthelsen; Ib Jarle Christensen; Carsten L Fagö-Olsen; Rune Fisker; Estrid V S Høgdall; Kirsten Jochumsen; Annika Loft; Anne Lerberg Nielsen; Ann Tabor; Erik Søgaard Andersen; Claus Høgdall
SUVmax of (18)FDG PET/CT as a predictor of high-risk endometrial cancer patients.
Gynecologic oncology 2013;129(2):298-303.
2013: Sofie Leisby Antonsen; Jon Asmussen; Anne Kiil Berthelsen; Ib Jarle Christensen; Junia Costa; Carsten L Fagö-Olsen; Rune Fisker; Mette Rodi Hansen; Estrid V S Høgdall; Lisa Neerup Jensen; Kirsten Jochumsen; Annika Loft; Lotte Nedergaard; Anne Lerberg Nielsen; Ingelise Qvist; Lene Sperling; Ann Tabor; Erik Søgaard Andersen; Claus Høgdall
MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study.
Gynecologic oncology 2013;128(2):300-8.
2013: Morten H Sparholt; Lotte Nedergaard; Ib J Christensen; Mel C J Heeran; Claus K Høgdall; Estrid V S Høgdall
Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2013;121(1):38-44.
2012: Mona Aarenstrup Karlsen; Inga Alice Laursen; Lene Lundvall; Magnus Lydolph; Lotte Nedergaard; Anette Tønnes Pedersen; Noreen Sandhu; Ib Jarle Christensen; Svend A Engelholm; Dorthe Hartwell; Claus K Høgdall; Estrid V S Høgdall
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Gynecologic oncology 2012;127(2):379-83.
2012: Signe Risum; Anne Kiil Berthelsen; Svend A Engelholm; Estrid V S Høgdall; Annika Loft; Lene Lundvall; Lotte Nedergaard; Claus Høgdall
Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2012;22(7):1163-9.
2012: Mette T Faber; Claus Høgdall; Estrid V S Høgdall; Allan Jensen; Jan Blaakaer; Marie Søgaard; Susanne K Kjaer
Use of dairy products, lactose, and calcium and risk of ovarian cancer - results from a Danish case-control study.
Acta oncologica (Stockholm, Sweden) 2012;51(4):454-64.
2012: Fanny Håkansson; Dorthe Hartwell; Claus K Høgdall; Estrid V S Høgdall; Lene Lundvall; Lotte Nedergaard; Anette Tønnes Pedersen; Svend A Engelholm
Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
Acta obstetricia et gynecologica Scandinavica 2012;91(4):496-502.
2011: Claus Høgdall; Ib J Christensen; Svend A Engelholm; Eric T Fung; Dorthe Hartwell; Lee Lomas; Lene Lundvall; Lotte Nedergaard; Anette T Pedersen; Anette L Petri; Signe Risum; Christine Yip; Estrid V S Høgdall
A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer.
Gynecologic oncology 2011;123(2):308-13.
2011: Signe Risum; Anne Loft; Claus K Høgdall; Anne Kiil Berthelsen; Estrid V S Høgdall; Lene Lundvall; Lotte Nedergaard; Svend A Engelholm
Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
Acta oncologica (Stockholm, Sweden) 2011;50(3):415-9.
2010: Estrid V S Høgdall; Eric T Fung; Ib Jarle Christensen; Christine Yip; Lotte Nedergaard; Svend A Engelholm; Signe Risum; Anette Lykke Petri; Lene Lundvall; Lee Lomas; Claus K Høgdall
Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients.
Proteomics. Clinical applications 2010;4(12):940-52.
2010: Estrid V S Høgdall; Lise Christensen; Susanne K Kjaer; Jan Blaakaer; Ib Jarle Christensen; Claus K Høgdall
Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2010;118(8):557-64.
2010: Farah Diba Begum; Estrid V S Høgdall; Ib Jarle Christensen; Lise Christensen; Susanne Krüger Kjaer; Jan Blaakaer; Anette Lykke Petri; Claus K Høgdall
Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients.
Gynecologic oncology 2010;117(3):446-50.
2010: Anette Lykke Petri; Anja Hviid Simonsen; Estrid V S Høgdall; Ib Jarle Christensen; Susanne Krüger Kjaer; Christine Yip; Signe Risum; Anette Tønnes Pedersen; Dorte Hartwell; Eric T Fung; Claus Høgdall
Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis.
Proteomics. Clinical applications 2010;4(3):304-14.
2010: Signe Risum; Claus K Høgdall; Anne Loft; Anne Kiil Berthelsen; Estrid V S Høgdall; L Nedergaard; Lene Lundvall; Svend A Engelholm
Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?
Gynecologic oncology 2010;116(3):395-8.
2009: Morten H Sparholt; Estrid V S Høgdall; Claus K Høgdall
[Tumour markers in epithelial ovarian cancer].
Ugeskrift for laeger 2009;171(48):3505-9.
2009: Søren Daugaard; Lise H Christensen; Estrid V S Høgdall
Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2009;117(7):518-25.
2009: Signe Risum; Claus Høgdall; Elena Markova; Anne K Berthelsen; Annika Loft; Flemming Jensen; Estrid V S Høgdall; Henrik Roed; Svend A Engelholm
Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(4):600-4.
2009: Marie Soegaard; Kirsten Frederiksen; Allan Jensen; Estrid V S Høgdall; Claus K Høgdall; Jan Blaakaer; Susan J Ramus; Simon A Gayther; Susanne Krüger Kjaer
Risk of ovarian cancer in women with first-degree relatives with cancer.
Acta obstetricia et gynecologica Scandinavica 2009;88(4):449-56.
2008: Anette Lykke Petri; Claus Høgdall; Ib Jarle Christensen; Anja Hviid Simonsen; Davy T'jampens; Marja-Leena Hellmann; Susanne Krüger Kjaer; Eric T Fung; Estrid V S Høgdall
Sample handling for mass spectrometric proteomic investigations of human urine.
Proteomics. Clinical applications 2008;2(9):1184-93.
2008: Estrid V S Høgdall; Lise Christensen; Susanne K Kjaer; Jan Blaakaer; Ib Jarle Christensen; Simon Gayther; Ian J Jacobs; Claus K Høgdall
Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study.
Pathology 2008;40(5):487-92.
2008: Marie Soegaard; Allan Jensen; Kirsten Frederiksen; Estrid V S Høgdall; Claus K Høgdall; Jan Blaakaer; Susanne K Kjaer
Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer.
Cancer causes & control : CCC 2008;19(5):469-79.
2008: Estrid V S Høgdall; Lise Christensen; Claus K Høgdall; Kirsten Frederiksen; Simon Gayther; Jan Blaakaer; Ian J Jacobs; Susanne K Kjaer
Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2008;116(5):400-9.
2008: S Risum; Claus K Høgdall; Anne Loft; Anne Kiil Berthelsen; Estrid V S Høgdall; L Nedergaard; Lene Lundvall; Svend A Engelholm
Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study.
Gynecologic oncology 2008;108(2):265-70.
2007: Estrid V S Høgdall; Lise Christensen; Claus K Høgdall; Jan Blaakaer; Simon A Gayther; Ian J Jacobs; Ib Jarle Christensen; Susanne Krüger Kjaer
Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Oncology reports 2007;18(5):1051-9.
2007: Anette Lykke Petri; Estrid V S Høgdall; Svend A Engelholm; Ib Jarle Christensen; Susanne Krüger Kjaer; Claus K Høgdall
[Identification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?].
Ugeskrift for laeger 2007;169(33):2614-9.
2007: Estrid V S Høgdall; Lise Christensen; Susanne Krüger Kjaer; Jan Blaakaer; Ib Jarle Christensen; Simon A Gayther; Ian J Jacobs; Claus K Høgdall
Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Gynecologic oncology 2007;106(2):318-24.
2007: Marie Soegaard; Allan Jensen; Estrid V S Høgdall; Lise Christensen; Claus K Høgdall; Jan Blaakaer; Susanne Krüger Kjaer
Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(6):1160-6.
2007: Signe Risum; Claus K Høgdall; Anne Loft; Anne Kiil Berthelsen; Estrid V S Høgdall; Lotte Nedergaard; Lene Lundvall; Svend A Engelholm
The diagnostic value of PET/CT for primary ovarian cancer--a prospective study.
Gynecologic oncology 2007;105(1):145-9.
2007: Merete Ringsholt; Estrid V S Høgdall; Julia S Johansen; Paul A Price; Lise H Christensen
YKL-40 protein expression in normal adult human tissues--an immunohistochemical study.
Journal of molecular histology 2007;38(1):33-43.
2007: Estrid V S Høgdall; Lise Christensen; Susanne Krüger Kjaer; Jan Blaakaer; Anette Kjaerbye-Thygesen; Simon A Gayther; Ian J Jacobs; Claus K Høgdall
CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
Gynecologic oncology 2007;104(3):508-15.
2007: Mikkel West-Nørager; Christian Dahl Kelstrup; Christian Schou; Estrid V S Høgdall; Claus K Høgdall; Niels H H Heegaard
Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;847(1):30-7.
2006: Susanne Krüger Kjaer; Estrid V S Høgdall; Kirsten Frederiksen; Christian Munk; Adriaan J C van den Brule; Edith Ingerslev Svare; Chris Meijer; Attilla Lorincz; Thomas Iftner
The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period.
Cancer research 2006;66(21):10630-6.
2006: Farah Diba Begum; Estrid V S Høgdall; Rikke Riisbro; Ib Jarle Christensen; Svend A Engelholm; Morten Jørgensen; Bent Nørgaard Pedersen; Claus K Høgdall
Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2006;114(10):675-81.
2006: Lene Drasbek Huusom; Kirsten Frederiksen; Estrid V S Høgdall; Eva Glud; Lise Christensen; Claus K Høgdall; Jan Blaakaer; Susanne Krüger Kjaer
Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study.
Cancer causes & control : CCC 2006;17(6):821-9.
2006: Bo Gronlund; Estrid V S Høgdall; Ib Jarle Christensen; Julia S Johansen; Bent Nørgaard-Pedersen; Svend A Engelholm; Claus K Høgdall
Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).
The International journal of biological markers 2006;21(3):141-8.
2006: Anette Lykke Petri; Estrid V S Høgdall; Ib Jarle Christensen; Susanne Krüger Kjaer; Jan Blaakaer; Claus K Høgdall
Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2006;114(5):359-63.
2006: Anette Kjaerbye-Thygesen; Kirsten Frederiksen; Estrid V S Høgdall; Eva Glud; Lise Christensen; Claus K Høgdall; Jan Blaakaer; Susanne Krüger Kjaer
Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(4):798-803.
2006: Anette Kjaerbye-Thygesen; Kirsten Frederiksen; Estrid V S Høgdall; Claus K Høgdall; Jan Blaakaer; Susanne Krüger Kjaer
Do risk factors for epithelial ovarian cancer have an impact on prognosis? Focus on previous pelvic surgery and reproductive variables.
European journal of gynaecological oncology 2006;27(5):467-72.
2006: Estrid V S Høgdall; Susanne Krüger Kjaer; Jan Blaakaer; Lise Christensen; Eva Glud; Jens Vuust; Claus K Høgdall
P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
Gynecologic oncology 2006;100(1):76-82.
2005: Stig E Bojesen; S K Kjaer; Estrid V S Høgdall; B L Thomsen; C K Høgdall; Jan Blaakaer; Anne Tybjaerg-Hansen; Børge G Nordestgaard
Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotes.
Endocrine-related cancer 2005;12(4):945-52.
2005: Bo Gronlund; H Dehn; Claus K Høgdall; Svend A Engelholm; Morten Jørgensen; Bent Nørgaard-Pedersen; Estrid V S Høgdall
Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2005;15(5):836-43.
2005: Mikkel West-Nielsen; Estrid V S Høgdall; Elena Marchiori; Claus K Høgdall; Christian Schou; Niels H H Heegaard
Sample handling for mass spectrometric proteomic investigations of human sera.
Analytical chemistry 2005;77(16):5114-23.
2004: Eva Glud; Susanne Krüger Kjaer; Birthe L Thomsen; Claus K Høgdall; Lise Christensen; Estrid V S Høgdall; Johannes E Bock; Jan Blaakaer
Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
Archives of internal medicine 2004;164(20):2253-9.
2004: Bo Gronlund; Claus K Høgdall; Jørgen Hilden; Svend A Engelholm; Estrid V S Høgdall; Heine H Hansen
Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(20):4051-8.
2004: Estrid V S Høgdall; Andy Ryan; Susanne Krüger Kjaer; Jan Blaakaer; Lise Christensen; Johannes E Bock; Eva Glud; Ian J Jacobs; Claus K Høgdall
Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Cancer 2004;100(11):2387-95.
2004: Farah Diba Begum; Claus K Høgdall; Susanne Krüger Kjaer; Lise Christensen; Jan Blaakaer; Johannes E Bock; Eva Glud; Gunilla Høyer-Hansen; Helmer Ring-Larsen; Estrid V S Høgdall
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Anticancer research 2004;24(3b):1981-5.
2004: Bo Gronlund; Heine H Hansen; Claus K Høgdall; Estrid V S Høgdall; Svend A Engelholm
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
British journal of cancer 2004;90(2):377-82.
2003: Estrid V S Høgdall; Julia S Johansen; Susanne Krüger Kjaer; Paul A Price; Lise Christensen; Jan Blaakaer; Johannes E Bock; Eva Glud; Claus K Høgdall
High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.
Oncology reports 2003;10(5):1535-8.
2003: Mads N Holten-Andersen; Anne-Sofie Schrohl; Nils Brünner; Hans Jørgen Nielsen; Claus K Høgdall; Estrid V S Høgdall
Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay.
The International journal of biological markers 2003;18(3):170-6.
2003: Estrid V S Høgdall; Susanne Krüger Kjaer; Eva Glud; Lise Christensen; Jan Blaakaer; Jens Vuust; Johannes E Bock; Bent Norgaard-Pedersen; Claus K Hogdall
Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study.
Anticancer research 2003;23(4):3397-404.
2003: Estrid V S Høgdall; Lise Christensen; Susanne Krüger Kjaer; Jan Blaakaer; Johannes E Bock; Eva Glud; Bent Nørgaard-Pedersen; Claus K Høgdall
Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
Cancer 2003;98(1):66-73.
2003: Estrid V S Høgdall; Claus K Høgdall; Jan Blaakaer; Lise Christensen; Johannes E Bock; Jens Vuust; Eva Glud; Susanne Krüger Kjaer
K-ras alterations in Danish ovarian tumour patients. From the Danish "Malova" Ovarian Cancer study.
Gynecologic oncology 2003;89(1):31-6.
2003: Hannah Dehn; Estrid V S Høgdall; Julia S Johansen; Morten Jørgensen; Paul A Price; Svend A Engelholm; Claus K Høgdall
Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Acta obstetricia et gynecologica Scandinavica 2003;82(3):287-93.
2002: Estrid V S Høgdall; Claus K Høgdall; Jan Blaakaer; Niels H H Heegaard; Eva Glud; Lise Christensen; Johannes E Bock; Bent Nørgaard-Pedersen; Allan Wiik; Susanne Krüger Kjaer
P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2002;110(7-8):545-53.
2002: Estrid V S Høgdall; Claus K Høgdall; Lise Christensen; Eva Glud; Jan Blaakaer; Johannes E Bock; Jens Vuust; Bent Nørgaard-Pedersen; Susanne Krüger Kjaer
Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients.
Anticancer research 2002;22(3):1859-64.
2002: Michael Christiansen; Estrid V S Høgdall; Severin Olesen Larsen; Claus K Høgdall
The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down syndrome.
Prenatal diagnosis 2002;22(5):385-7.
2001: R Riisbro; I J Christensen; Claus K Høgdall; N Brünner; Estrid V S Høgdall
Soluble urokinase plasminogen activator receptor measurements: influence of sample handling.
The International journal of biological markers 2001;16(4):233-9.
2000: X Deng; Estrid V S Høgdall; Claus K Høgdall; Bent Nørgaard-Pedersen; Morten Jørgensen; H Nielsen; Svend A Engelholm
The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer.
Gynecologic oncology 2000;79(3):416-9.
2000: Estrid V S Høgdall; Julia S Johansen; Susanne Krüger Kjaer; Paul A Price; J Blaakjaer; Claus K Høgdall
Stability of YKL-40 concentration in blood samples.
Scandinavian journal of clinical and laboratory investigation 2000;60(4):247-51.
2000: Estrid V S Høgdall; Jens Vuust; P Lind; Eskild Petersen
Characterisation of Toxoplasma gondii isolates using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) of the non-coding Toxoplasma gondii (TGR)-gene sequences.
International journal for parasitology 2000;30(7):853-8.
2000: Michael Christiansen; Claus K Høgdall; Estrid V S Høgdall
Alpha-fetoprotein in human fetal cerebrospinal fluid.
Clinica chimica acta; international journal of clinical chemistry 2000;291(1):35-41.
1999: Bodil Laub Petersen; Estrid V S Høgdall; N Kryger-Baggesen
Metastasis to the breast from an ovarian carcinoma.
Acta obstetricia et gynecologica Scandinavica 1999;78(9):826-7.
1999: Estrid V S Høgdall; Kit Boye; Jens Vuust
Simple preparation method of PCR fragments for automated DNA sequencing.
Journal of cellular biochemistry 1999;73(4):433-6.
1999: Kit Boye; Estrid V S Høgdall; Martin B Borre
Identification of bacteria using two degenerate 16S rDNA sequencing primers.
Microbiological research 1999;154(1):23-6.
1998: Estrid V S Høgdall; Gunnar Houen; Martin B Borre; Jens R Bundgaard; Lars-Inge Larsson; Jens Vuust
Structure and tissue-specific expression of genes encoding bovine copper amine oxidases.
European journal of biochemistry / FEBS 1998;251(1-2):320-8.
1996: Claus K Høgdall; Estrid V S Høgdall; U Hørding; K Toftager-Larsen; J Arends; Bent Nørgaard-Pedersen; I Clemmensen
Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
Acta oncologica (Stockholm, Sweden) 1996;35(1):63-9.
1994: Bent Nørgaard-Pedersen; Estrid V S Høgdall; J Arends; Jens Vuust
[Screening of newborn infants for cystic fibrosis. A combined analysis of immunoreactive trypsin and delta F508 mutation--a screening without false positive results].
Ugeskrift for laeger 1994;156(25):3757-60.
1993: Claus K Høgdall; Estrid V S Høgdall; U Hørding; I Clemmensen; Bent Nørgaard-Pedersen; K Toftager-Larsen
Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients.
Scandinavian journal of clinical and laboratory investigation 1993;53(7):741-6.
1993: A G Loft; Estrid V S Høgdall; Severin Olesen Larsen; Bent Nørgaard-Pedersen
A comparison of amniotic fluid alpha-fetoprotein and acetylcholinesterase in the prenatal diagnosis of open neural tube defects and anterior abdominal wall defects.
Prenatal diagnosis 1993;13(2):93-109.
1992: A Iitiä; Estrid V S Høgdall; P Dahlen; P Hurskainen; Jens Vuust; H Siitari
Detection of mutation delta F508 in the cystic fibrosis gene using allele-specific PCR primers and time-resolved fluorometry.
PCR methods and applications 1992;2(2):157-62.
1992: Claus K Høgdall; Estrid V S Høgdall; L N Jørgensen; I Clemmensen
Changes in plasma tetranectin following hip surgery with or without thrombotic complications.
Thrombosis research 1992;67(4):399-405.
1992: Claus K Høgdall; Estrid V S Høgdall; J Arends; Bent Nørgaard-Pedersen; S Smidt-Jensen; Severin Olesen Larsen
CA-125 as a maternal serum marker for Down's syndrome in the first and second trimesters.
Prenatal diagnosis 1992;12(3):223-7.
1991: Estrid V S Høgdall; Claus K Høgdall
[15(S)-15-methyl-prostaglandin F2 alpha. A potent synthetic prostaglandin F2 alpha for treatment of postpartum atony].
Ugeskrift for laeger 1991;153(46):3260-2.
1991: Claus K Høgdall; Estrid V S Høgdall; U Hørding; S Daugaard; I Clemmensen; Bent Nørgaard-Pedersen; K Toftager-Larsen
Plasma tetranectin and ovarian neoplasms.
Gynecologic oncology 1991;43(2):103-7.
1991: Estrid V S Høgdall; Claus K Høgdall; I Clemmensen; Bent Nørgaard-Pedersen; A G Loft
Tetranectin in amniotic fluid, maternal serum and fetal fluids.
Scandinavian journal of clinical and laboratory investigation 1991;51(5):411-5.
1989: C K Høgdall; Estrid V S Høgdall
[Treatment of severe postpartum atony with prostaglandin].
Ugeskrift for laeger 1989;151(38):2410-3.